Segment Information

3 Months Ended

Apr. 02, 2016

Segment Reporting [Abstract]

Segment Information

SEGMENT INFORMATION

Our reporting segments are as follows:

• CHCis focused primarily on the global sale of OTC store brand products including cough, cold, allergy, and sinus, analgesic, gastrointestinal, smoking cessation, infant formula and food, VMS, animal health, and diagnostic products.

• BCHdevelops, manufactures, markets and distributes many well-known European OTC brands in the natural health and VMS, cough, cold and allergy, smoking cessation, personal care and derma-therapeutics, lifestyle, and anti-parasite categories.

• Rxdevelops, manufactures and markets a portfolio of generic and specialty pharmaceutical prescription drugs primarily for the U.S. and U.K. markets.

• Specialty Sciences is comprised primarily of royalties received from assets focused on the management of multiple sclerosis (Tysabri^®).

We also have an "Other" segment that is comprised of our API business, which does not meet the quantitative threshold required to be a separately reportable segment. Our segments reflect the way in which our chief operating decision maker reviews our operating results and allocates resources.

The below tables show select financial measures by reporting segment (in millions):

	Three Months Ended							April 2, 2016
	April 2, 2016
	Restated							Restated
	Net Sales		Operating Income (Loss)			Amortization of Intangibles		Total Assets
CHC	$	700.3	$	99.5		$	19.8	$	3,742.7
BCH	362.8		(398.1		)	35.5		6,416.3
Rx	263.6		94.3			29.5		3,384.5
Specialty Sciences	—		(1.4		)	—		5,738.8
Other	20.6		5.4			0.5		217.4
Unallocated	—		(31.3		)			—
Total	$	1,347.3	$	(231.6	)	$	85.3	$	19,499.7

	Three Months Ended							December 31, 2015
	March 28, 2015
	Restated							Restated
	Net Sales		Operating Income (Loss)			Amortization of Intangibles		Total Assets
CHC	$	684.9	$	104.3		$	16.1	$	3,384.8
BCH	—		—			—		7,083.5
Rx	251.6		100.0			18.3		2,738.0
Specialty Sciences	—		(3.3		)	0.3		5,930.2
Other	30.7		10.5			0.5		213.1
Unallocated	—		(21.1		)	—		—
Total	$	967.2	$	190.4		$	35.2	$	19,349.6

The Specialty Sciences segment recognized expense (income) of $204.4 million and $(100.8) million for the three months ended April 2, 2016 and March 28, 2015, respectively, for the change in the fair value of the Tysabri^® royalty stream during each period.